Effect of weekly 17-hydroxyprogesterone caproate on small for gestational age among pregnant women with HIV in Zambia.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 11 2022
15 11 2022
Historique:
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
1
11
2022
Statut:
ppublish
Résumé
The IPOP trial demonstrated a reduced risk of severe small for gestational age among infants born to women with HIV who received weekly intramuscular 17 alpha-hydroxyprogesterone caproate. This secondary analysis examined the 17P treatment effect in subgroups of maternal BMI, parity, timing of antiretroviral therapy (ART) initiation, and ART regimen. We found that 17P was more effective among nulliparous women, women who started ART before pregnancy, and those taking protease inhibitors.
Identifiants
pubmed: 36305188
doi: 10.1097/QAD.0000000000003362
pii: 00002030-202211150-00024
pmc: PMC9624437
mid: NIHMS1835452
doi:
Substances chimiques
17 alpha-Hydroxyprogesterone Caproate
276F2O42F5
17-alpha-Hydroxyprogesterone
68-96-2
Hydroxyprogesterones
0
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2079-2081Subventions
Organisme : NICHD NIH HHS
ID : R01 HD087119
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010558
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009340
Pays : United States
Organisme : FIC NIH HHS
ID : K01 TW010857
Pays : United States
Organisme : NICHD NIH HHS
ID : T32 HD075731
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Wedi CO, Kirtley S, Hopewell S, Corrigan R, Kennedy SH, Hemelaar J. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis . Lancet HIV 2016; 3:e33–48.
Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: a cohort study . J Infect Dis 2016; 213:1057–1064.
Mohammadi H, Papp E, Cahill L, Rennie M, Banko N, Pinnaduwage L, et al. HIV antiretroviral exposure in pregnancy induces detrimental placenta vascular changes that are rescued by progesterone supplementation . Sci Rep 2018; 8:6552.
Price JT, Vwalika B, Freeman BL, Cole SR, Saha PT, Mbewe FM, et al. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial . Lancet HIV 2021; 8:10.
Price JT, Vwalika B, Freeman BL, Cole SR, Mulenga HB, Winston J, et al. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial . BMC Pregnancy Childbirth 2019; 19:81.
Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project . Lancet 2014; 384:857–868.